Trial Profile
Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Condylomata acuminata; Gynaecological cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Merck & Co
- 04 Dec 2015 New trial record